糖尿病肾病早期诊断标志物的研究新进展

摘要

糖尿病肾病 (diabetic kidney disease,DKD)是2型糖尿病病人 (type 2 diabetes mellitus,T2DM)最常见、最严重的慢性合并症,发病率逐年升高,已成为危害人类的重大疾病.早期经治疗后多可逆转,晚期则发展成终末期肾病.因此,及早诊断和预测DKD对临床治疗显得尤为重要.目前,临床上以微量白蛋白尿(microalbuminuria,MAU)作为诊断2型糖尿病肾损害的早期指标,然而,其预测价值受到质疑.近年来,人们发现蛋白质组学可能成为诊断糖尿病肾病的新工具,触珠蛋白(haptoglobin,HP)这种多功能的急性期时相蛋白可能与DKD的发生及发展密切相关.因此,本文就触珠蛋白与糖尿病肾病发病机制的研究进展进行综述.%Diabetic kidney disease (DKD) as a common and severe chronic complication of type 2 diabetes mellitus (T2DM) has rapidly become an important public health problem.It can be reversed in early stage after treatment,or become end-stage renal disease in advanced stage.Therefore,early diagnosis and prediction of DKD for clinical treatment is particularly important.Although microalbuminuria (MAU) is an early marker for kidney damage in type 2 diabetes mellitus,its predictive value is now questioned.In recent years,it was found that proteomics may become a new tool in the diagnosis of diabetic nephropathy.Haptoglobin (HP) as an acute phase protein with a variety of functions was found may be closely related to the occurrence and development of diabetic nephropathy.Therefore,this article reviewed the progress on research of haptoglobin with the pathogenesis of diabetic nephropathy.